{"generic":"Ethinyl Estradiol\/Norgestimate","drugs":["Ethinyl Estradiol\/Norgestimate","MonoNessa","Ortho Tri-Cyclen","Ortho Tri-Cyclen Lo","Ortho-Cyclen","Previfem","Sprintec","Tri-Previfem","Tri-Sprintec"],"mono":[{"id":"8smcs0","title":"Generic Names","mono":"Ethinyl Estradiol\/Norgestimate"},{"id":"8smcs1","title":"Dosing and Indications","sub":{"0":{"id":"8smcs1b4","title":"Adult Dosing","mono":"<ul><li>If switching from an oral contraceptive, start first dose on the same day that a new pack of the previous oral contraceptive would have started; if switching from a transdermal patch, start first dose on the day when the next patch would have been applied; if switching from a vaginal ring, start first dose on the day when the next ring would have been inserted; if switching from a contraception injection, start first dose on the day the next injection is due; if switching from a contraceptive intrauterine device (IUD), start first dose on the day the intrauterine contraceptive is removed, and use additional nonhormonal contraception (eg, condoms or spermicide) for the first 7 days of the first pack if the intrauterine contraceptive is not removed on the first day of menses; if switching from a contraceptive implant, start first dose on same day the implant is removed.<\/li><li><b>Acne:<\/b> 1 tablet ORALLY daily at the same time of day: 1 white (active) tablet daily for 7 consecutive days, then 1 light blue (active) tablet daily for 7 consecutive days, then 1 blue (active) tablet daily for 7 consecutive days, then 1 green (placebo) tablet daily for 7 consecutive days; repeat cycle<\/li><li><b>Acne:<\/b> Begin therapy on first day of menstrual cycle or on the first Sunday after the start of the menstrual cycle; a nonhormonal backup method of contraception is recommended for the first 7 days of therapy if dosing starts on a day other than the first day of menstrual cycle.<\/li><li><b>Acne:<\/b> Therapy may be initiated 4 weeks postpartum in nonlactating women. If menses has not started postpartum, consider the possibility of conception prior to therapy initiation.<\/li><li><b>Acne:<\/b> Therapy may be initiated immediately after a first-trimester abortion or miscarriage; use additional nonhormonal contraception (eg, condoms or spermicide) for the first 7 days of the first pack if not started within 5 days of abortion or miscarriage.<\/li><li><b>Acne:<\/b> Therapy may be initiated 4 weeks following a second-trimester abortion or miscarriage. For Sunday starters, use additional nonhormonal contraception (eg, condoms or spermicide) for the first 7 days of the first pack.<\/li><li><b>Contraception:<\/b> Ortho-Cyclen(R), 1 tablet ORALLY daily at the same time of day: 1 blue (active) tablet daily for 21 consecutive days, then 1 green (placebo) tablet daily for 7 days; repeat cycle<\/li><li><b>Contraception:<\/b> Ortho Tri-Cyclen(R), 1 tablet ORALLY daily at the same time of day: 1 white (active) tablet daily for 7 consecutive days, then 1 light blue (active) tablet daily for 7 consecutive days, then 1 blue (active) tablet daily for 7 consecutive days, then 1 green (placebo) tablet daily for 7 consecutive days; repeat cycle<\/li><li><b>Contraception:<\/b> Ortho Tri-Cyclen(R) Lo: 1 tablet ORALLY daily at the same time of day: 1 white (active) tablet daily for 7 consecutive days, then 1 light blue (active) tablet daily for 7 consecutive days, then 1 blue (active) tablet daily for 7 consecutive days, then 1 green (placebo) tablet daily for 7 consecutive days; repeat cycle<\/li><li><b>Contraception:<\/b> Begin therapy on first day of menstrual cycle or on the first Sunday after the start of the menstrual cycle; a nonhormonal backup method of contraception is recommended for the first 7 days of therapy if dosing starts on a day other than the first day of menstrual cycle.<\/li><li><b>Contraception:<\/b> Therapy may be initiated 4 weeks postpartum in nonlactating women. If menses has not started postpartum, consider the possibility of conception prior to therapy initiation.<\/li><li><b>Contraception:<\/b> Therapy may be initiated immediately after a first-trimester abortion or miscarriage; use additional nonhormonal contraception (eg, condoms or spermicide) for the first 7 days of the first pack if not started within 5 days of abortion or miscarriage.<\/li><li><b>Contraception:<\/b> Therapy may be initiated 4 weeks following a second-trimester abortion or miscarriage. For Sunday starters, use additional nonhormonal contraception (eg, condoms or spermicide) for the first 7 days of the first pack.<\/li><\/ul>"},"1":{"id":"8smcs1b5","title":"Pediatric Dosing","mono":"<ul><li>Use before menarche is not indicated.<\/li><li>If switching from an oral contraceptive, start first dose on the same day that a new pack of the previous oral contraceptive would have started; if switching from a transdermal patch, start first dose on the day when the next patch would have been applied; if switching from a vaginal ring, start first dose on the day when the next ring would have been inserted; if switching from a contraception injection, start first dose on the day the next injection is due; if switching from a contraceptive intrauterine device (IUD), start first dose on the day the intrauterine contraceptive is removed, and use additional nonhormonal contraception (eg, condoms or spermicide) for the first 7 days of the first pack if the intrauterine contraceptive is not removed on the first day of menses; if switching from a contraceptive implant, start first dose on same day the implant is removed.<\/li><li><b>Acne:<\/b> 1 tablet ORALLY daily at the same time of day: 1 white (active) tablet daily for 7 consecutive days, then 1 light blue (active) tablet daily for 7 consecutive days, then 1 blue (active) tablet daily for 7 consecutive days, then 1 green (placebo) tablet daily for 7 consecutive days; repeat cycle<\/li><li><b>Acne:<\/b> Begin therapy on first day of menstrual cycle or on the first Sunday after the start of the menstrual cycle; a nonhormonal backup method of contraception is recommended for the first 7 days of therapy if dosing starts on a day other than the first day of menstrual cycle.<\/li><li><b>Acne:<\/b> Therapy may be initiated 4 weeks postpartum in nonlactating women. If menses has not started postpartum, consider the possibility of conception prior to therapy initiation.<\/li><li><b>Acne:<\/b> Therapy may be initiated immediately after a first-trimester abortion or miscarriage; use additional nonhormonal contraception (eg, condoms or spermicide) for the first 7 days of the first pack if not started within 5 days of abortion or miscarriage.<\/li><li><b>Acne:<\/b> Therapy may be initiated 4 weeks following a second-trimester abortion or miscarriage. For Sunday starters, use additional nonhormonal contraception (eg, condoms or spermicide) for the first 7 days of the first pack.<\/li><li><b>Contraception:<\/b> Ortho-Cyclen(R), 1 tablet ORALLY daily at the same time of day: 1 blue (active) tablet daily for 21 consecutive days, then 1 green (placebo) tablet daily for 7 days; repeat cycle<\/li><li><b>Contraception:<\/b> Ortho Tri-Cyclen(R) or, 1 tablet ORALLY daily at the same time of day: 1 white (active) tablet daily for 7 consecutive days, then 1 light blue (active) tablet daily for 7 consecutive days, then 1 blue (active) tablet daily for 7 consecutive days, then 1 green (placebo) tablet daily for 7 consecutive days; repeat cycle<\/li><li><b>Contraception:<\/b> Ortho Tri-Cyclen(R) Lo: 1 tablet ORALLY daily at the same time of day: 1 white (active) tablet daily for 7 consecutive days, then 1 light blue (active) tablet daily for 7 consecutive days, then 1 blue (active) tablet daily for 7 consecutive days, then 1 green (placebo) tablet daily for 7 consecutive days; repeat cycle<\/li><li><b>Contraception:<\/b> Begin therapy on first day of menstrual cycle or on the first Sunday after the start of the menstrual cycle; a nonhormonal backup method of contraception is recommended for the first 7 days of therapy if dosing starts on a day other than the first day of menstrual cycle.<\/li><li><b>Contraception:<\/b> Therapy may be initiated 4 weeks postpartum in nonlactating women. If menses has not started postpartum, consider the possibility of conception prior to therapy initiation.<\/li><li><b>Contraception:<\/b> Therapy may be initiated immediately after a first-trimester abortion or miscarriage; use additional nonhormonal contraception (eg, condoms or spermicide) for the first 7 days of the first pack if not started within 5 days of abortion or miscarriage.<\/li><li><b>Contraception:<\/b> Therapy may be initiated 4 weeks following a second-trimester abortion or miscarriage. For Sunday starters, use additional nonhormonal contraception (eg, condoms or spermicide) for the first 7 days of the first pack.<\/li><\/ul>"},"3":{"id":"8smcs1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Acne<\/li><li>Contraception<\/li><\/ul>"}}},{"id":"8smcs2","title":"Black Box Warning","mono":"<b>Oral (Tablet)<\/b><br\/>Ortho-Cyclen(R), Ortho Tri-Cyclen(R): Cigarette smoking increases the risk of serious cardiovascular side effects from combination oral contraceptive use. This risk increases with age and the number of cigarettes smoked and is quite marked in women over 35 years of age. Use of combination oral contraceptives is contraindicated in women over the age of 35 who smoke; Ortho Tri-Cyclen(R) Lo: Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.<br\/>"},{"id":"8smcs3","title":"Contraindications\/Warnings","sub":[{"id":"8smcs3b9","title":"Contraindications","mono":"<ul><li>Arterial or venous thrombotic diseases, patients at high risk<\/li><li>Breast cancer or other estrogen-or progestin-sensitive cancer, history of or current<\/li><li>Cerebrovascular disease<\/li><li>Coronary artery disease<\/li><li>Diabetes mellitus with vascular disease<\/li><li>DVT or pulmonary embolism, history of or current<\/li><li>Headaches with focal neurological symptoms<\/li><li>Hypercoagulopathies, inherited or acquired<\/li><li>Hypertension, uncontrolled<\/li><li>Liver disease or liver tumors, benign or malignant<\/li><li>Migraine headaches in patients older than 35 years<\/li><li>Migraine headaches with aura<\/li><li>Pregnancy<\/li><li>Smoking, women older than 35 years<\/li><li>Thrombogenic valvular or thrombogenic rhythm diseases of the heart (eg, atrial fibrillation or subacute bacterial endocarditis with valvular disease)<\/li><li>Uterine bleeding, undiagnosed abnormal<\/li><\/ul>"},{"id":"8smcs3b10","title":"Precautions","mono":"<ul><li>Black Box Warning:<\/li><li>-- Cigarette smoking and over the age of 35; increased risk of serious cardiovascular side effects, including myocardial infarction<\/li><li>Cardiovascular:<\/li><li>-- Cardiovascular disease risk factors  (diabetes, hyperlipidemias, hypertension, obesity); increased risk of morbidity and mortality<\/li><li>-- Venous thromboembolism risk increased, highest during first year of use or when restarting hormonal contraceptive after break of 4 weeks or more; increased risk if predisposing conditions for VTE disease exist; risk gradually decreases after discontinuation<\/li><li>-- Myocardial infarction; increased risk has been reported, primarily in smokers or women with underlying coronary artery disease risk factors<\/li><li>-- Arterial or venous thrombotic event; discontinue use<\/li><li>-- Hypertension, well-controlled; monitoring recommended and discontinue if significant blood pressure elevation occurs; blood pressure elevation has occurred particularly in older users and with extended duration of use, and with increasing progestin concentrations<\/li><li>-- History of hypertension, hypertension-related disease, or renal disease; consider alternate form of contraception<\/li><li>-- Postoperative thromboembolic complications; increased risk reported; discontinue oral contraceptives at least 4 weeks prior to and for 2 weeks after major or other surgeries associated with an increased risk of thromboembolism, and during periods of prolonged immobilization<\/li><li>-- Persistence of risk of vascular disease, following discontinuation for ever-users of oral contraceptives has been reported<\/li><li>-- Dose-related risk of vascular disease from oral contraceptives<\/li><li>Dermatologic:<\/li><li>-- Chloasma may occur, especially in women with a history of chloasma gravidarum; patients with tendency for chloasma should avoid the sun and ultraviolet radiation during use<\/li><li>Endocrine and Metabolic:<\/li><li>-- Diabetes or prediabetes; glucose tolerance may be altered; monitoring recommended<\/li><li>-- Hyperlipidemias; changes in triglyceride and lipoprotein levels have been reported; monitoring recommended<\/li><li>-- Hypertriglyceridemia; increased risk of pancreatitis<\/li><li>-- Dyslipidemia, uncontrolled; consider alternative treatment<\/li><li>Thyroxine-binding globulin, sex hormone-binding globulin, cortisol-binding globulin serum concentrations may be increased; alterations to replacement thyroid or hormone therapy may be required<\/li><li>Gastrointestinal:<\/li><li>-- Gallbladder disease or worsening of existing gallbladder disease may occur; increased risk with past history of COC related cholestasis, and possibly with pregnancy-related cholestasis<\/li><li>-- Gallbladder disease requiring surgery has been reported<\/li><li>Hepatic:<\/li><li>-- Liver disease, including acute viral hepatitis or severe decompensated cirrhosis; do not initiate; discontinuation may be required for acute or chronic disturbances, discontinue if jaundice develops<\/li><li>-- Hepatic neoplasia has been reported; increased risk with use of 4 years or longer and higher-dose formulations; increased risk of hepatocellular carcinomas with greater than 8 years of use<\/li><li>Neurologic:<\/li><li>-- Cerebrovascular events; increased risk of thrombotic and hemorrhagic strokes, particularly in smokers older than 35 years of age who are hypertensive<\/li><li>-- Migraine; consider discontinuation if frequency or severity increases; may be prodrome of cerebrovascular event<\/li><li>-- New headaches that are recurrent, persistent, or severe; evaluate and discontinue use if indicated<\/li><li>Ophthalmic:<\/li><li>-- Unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions; discontinue use and evaluate for retinal vein thrombosis<\/li><li>-- Contact lens wearers who develop visual changes or changes in lens tolerance; evaluation by an ophthalmologist recommended<\/li><li>-- Retinal thrombosis has been reported; discontinue if there is unexplained partial or complete vision loss, onset of proptosis or diplopia, papilledema, or retinal vascular lesions and immediately undertake appropriate diagnostic and therapeutic measures<\/li><li>Psychiatric:<\/li><li>-- History of depression; monitoring recommended and discontinuation maybe necessary<\/li><li>Reproductive:<\/li><li>-- Immediate postpartum period; increased risk of thromboembolism; begin oral contraceptives no earlier than 4 weeks after delivery, in women not breastfeeding<\/li><li>-- Amenorrhea may occur; if patient missed one or more active tablets, or if scheduled bleeding does not occur, test for pregnancy<\/li><li>-- Unscheduled (breakthrough or intracyclic) bleeding and spotting may occur, especially during first 3 months of use; if bleeding persists after regular cycles, check for malignancy or pregnancy, and if pathology is excluded, consider alternate formulation<\/li><li>-- Breast cancer; an increased risk has been reported; monitoring recommended<\/li><li>-- Cervical intraepithelial neoplasia; an increased risk has been reported but findings are controversial<\/li><li>-- Ectopic or intrauterine pregnancy may occur<\/li><li>Other:<\/li><li>-- Fluid retention may occur; carefully monitor patients with conditions that may be exacerbated by fluid retention<\/li><li>-- HIV infection or sexually transmitted diseases; oral contraceptives offer no protection<\/li><li>-- Hereditary angioedema; may induce or exacerbate symptoms<\/li><\/ul>"},{"id":"8smcs3b11","title":"Pregnancy Category","mono":"Fetal risk has been demonstrated. (TH)<br\/>"},{"id":"8smcs3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},{"id":"8smcs4","title":"Drug Interactions","sub":[{"id":"8smcs4b13","title":"Contraindicated","mono":"<ul><li>Dasabuvir (theoretical)<\/li><li>Ombitasvir (established)<\/li><li>Paritaprevir (established)<\/li><li>Ritonavir (theoretical)<\/li><li>Tranexamic Acid (probable)<\/li><\/ul>"},{"id":"8smcs4b14","title":"Major","mono":"<ul><li>Anagrelide (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Boceprevir (probable)<\/li><li>Bupropion (theoretical)<\/li><li>Carbamazepine (probable)<\/li><li>Ceritinib (theoretical)<\/li><li>Clozapine (established)<\/li><li>Crizotinib (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Donepezil (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Felbamate (probable)<\/li><li>Fentanyl (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Isotretinoin (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Paclitaxel (theoretical)<\/li><li>Paclitaxel Protein-Bound (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Pirfenidone (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Theophylline (theoretical)<\/li><li>Tizanidine (probable)<\/li><li>Ulipristal (established)<\/li><\/ul>"},{"id":"8smcs4b15","title":"Moderate","mono":"<ul><li>Alprazolam (probable)<\/li><li>Amprenavir (probable)<\/li><li>Aprepitant (probable)<\/li><li>Atazanavir (probable)<\/li><li>Bacampicillin (probable)<\/li><li>Betamethasone (probable)<\/li><li>Bexarotene (probable)<\/li><li>Bosentan (probable)<\/li><li>Clarithromycin (probable)<\/li><li>Colesevelam (probable)<\/li><li>Cyclosporine (probable)<\/li><li>Delavirdine (probable)<\/li><li>Efavirenz (established)<\/li><li>Eslicarbazepine Acetate (probable)<\/li><li>Etoricoxib (probable)<\/li><li>Etravirine (probable)<\/li><li>Fosamprenavir (established)<\/li><li>Fosaprepitant (probable)<\/li><li>Fosphenytoin (probable)<\/li><li>Ginseng (probable)<\/li><li>Griseofulvin (established)<\/li><li>Lamotrigine (established)<\/li><li>Licorice (probable)<\/li><li>Modafinil (probable)<\/li><li>Mycophenolate Mofetil (probable)<\/li><li>Mycophenolic Acid (probable)<\/li><li>Nelfinavir (probable)<\/li><li>Oxcarbazepine (probable)<\/li><li>Phenobarbital (probable)<\/li><li>Phenytoin (probable)<\/li><li>Prednisolone (established)<\/li><li>Primidone (probable)<\/li><li>Rifabutin (probable)<\/li><li>Rifampin (established)<\/li><li>Rifapentine (probable)<\/li><li>Roflumilast (probable)<\/li><li>Rosuvastatin (probable)<\/li><li>Rufinamide (probable)<\/li><li>Selegiline (probable)<\/li><li>St John's Wort (established)<\/li><li>Telaprevir (established)<\/li><li>Tipranavir (established)<\/li><li>Topiramate (probable)<\/li><li>Troglitazone (probable)<\/li><li>Troleandomycin (established)<\/li><li>Valdecoxib (probable)<\/li><li>Voriconazole (established)<\/li><li>Warfarin (probable)<\/li><\/ul>"}]},{"id":"8smcs5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Chloasma<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (5.6% to 7.8%)<\/li><li><b>Neurologic:<\/b>Headache, Migraine<\/li><li><b>Psychiatric:<\/b>Depression, Mood disorder<\/li><li><b>Reproductive:<\/b>Amenorrhea, Discharge from female genitalia (3.2% to 6.8%), Discharge from the breast, Infective vaginitis (7.1% to 8.4%), Intermenstrual bleeding - irregular, Pain of breast, Swelling of breast<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Hypertension, Myocardial infarction<\/li><li><b>Gastrointestinal:<\/b>Disorder of gallbladder, Pancreatitis<\/li><li><b>Hematologic:<\/b>Arterial thrombosis, Venous thromboembolism<\/li><li><b>Hepatic:<\/b>Adenoma of liver, Liver carcinoma<\/li><li><b>Neurologic:<\/b>Cerebrovascular accident<\/li><\/ul>"},{"id":"8smcs6","title":"Drug Name Info","sub":{"0":{"id":"8smcs6b17","title":"US Trade Names","mono":"<ul><li>Ortho-Cyclen<\/li><li>Ortho Tri-Cyclen<\/li><li>Ortho Tri-Cyclen Lo<\/li><li>Previfem<\/li><li>Tri-Previfem<\/li><li>Sprintec<\/li><li>Tri-Sprintec<\/li><li>MonoNessa<\/li><\/ul>"},"2":{"id":"8smcs6b19","title":"Class","mono":"<ul><li>Contraceptive<\/li><li>Estrogen<\/li><li>Progestin<\/li><\/ul>"},"3":{"id":"8smcs6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"8smcs6b21","title":"Generic Availability","mono":"No<br\/>"}}},{"id":"8smcs7","title":"Mechanism Of Action","mono":"Ethinyl estradiol, an estrogen, and norgestimate, a progestin, are a combination product that reduces the possibility of pregnancy primarily via suppression of ovulation. The exact mechanism involved in the treatment of acne is not established, but may be related to increase of sex hormone-binding globulin and reduction of free testosterone.<br\/>"},{"id":"8smcs8","title":"Pharmacokinetics","sub":[{"id":"8smcs8b23","title":"Absorption","mono":"<ul><li>Ethinyl estradiol, oral: 1.13 to 1.32 hours<\/li><li>Norgestrel (active metabolite), oral: 1.67 to 3.15 hours<\/li><li>Norelgestromin (active metabolite), oral: 1.21 to 1.43 hours<\/li><\/ul>"},{"id":"8smcs8b24","title":"Distribution","mono":"<ul><li>Ethinyl estradiol, Protein binding: Greater than 97%, to serum albumin<\/li><li>Norelgestromin and norgestrel (active metabolites), Protein binding: Greater than 97%<\/li><\/ul>"},{"id":"8smcs8b25","title":"Metabolism","mono":"<ul><li>Ethinyl estradiol: Extensive, hydroxylation and conjugation<\/li><li>Metabolites: Hydroxylated products, glucuronide and sulfate conjugates<\/li><li>Norgestimate, Hepatic and Intestinal: Extensive, first-pass<\/li><li>Active metabolites: 17-deacetyl norgestimate, norelgestromin and norgestrel<\/li><\/ul>"},{"id":"8smcs8b26","title":"Excretion","mono":"<ul><li>Ethinyl estradiol, Fecal: Partial, as metabolites<\/li><li>Ethinyl estradiol, Renal: Partial<\/li><li>Norgestimate, Fecal: 37%, including metabolites<\/li><li>Norgestimate, Renal: 47%, as metabolites<\/li><\/ul>"},{"id":"8smcs8b27","title":"Elimination Half Life","mono":"<ul><li>Ethinyl estradiol: 15 to 15.9 hours<\/li><li>Norelgestromin: 22.3 to 24.9 hours<\/li><li>Norgestrel: 40.2 to 45 hours<\/li><\/ul>"}]},{"id":"8smcs9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>Take at the same time every day in the order on the dispenser.<\/li><li>Do not skip doses.<\/li><li>Missed doses (including vomiting or diarrhea within 3 to 4 hours after active dose): With 1 missed active dose, take as soon as possible, and continue taking 1 tablet orally daily until the pack is finished.<\/li><li>Missed doses (including vomiting or diarrhea within 3 to 4 hours after active dose): With 2 missed active doses in week 1 or 2, take 2 tablets as soon as possible, and then 2 tablets the following day. Continue taking 1 tablet daily until the pack is finished. Use additional nonhormonal contraception (eg, condoms or spermicide) for 7 days after the missed dose.<\/li><li>Missed doses (including vomiting or diarrhea within 3 to 4 hours after active dose): With 3 or more consecutive missed active doses in week 1, 2, or 3 OR 2 missed active doses in week 3: For day 1 staters, discard the rest of the pack and begin a new pack that same day. For Sunday starters, continue taking 1 tablet orally daily until Sunday, and then discard the rest of the pack and begin a new pack. Use additional nonhormonal contraception (eg, condoms or spermicide) for 7 days after the missed dose.<\/li><\/ul>"},{"id":"8smcs10","title":"Monitoring","mono":"<ul><li>Pregnancy prevention indicates efficacy<\/li><li>Patients with a history of depression<\/li><li>Blood pressure; annually, and more frequently in patients with well-controlled hypertension<\/li><li>Prediabetic and diabetic patients<\/li><li>Physical examination annually and breast examinations regularly<\/li><li>Patients with conditions that might be aggravated by fluid retention<\/li><\/ul>"},{"id":"8smcs11","title":"How Supplied","mono":"<b>Ortho-Cyclen<\/b><br\/>Oral Tablet: (Ethinyl Estradiol - Norgestimate) 35 MCG-0.25 MG<br\/>"},{"id":"8smcs12","title":"Toxicology","sub":[{"id":"8smcs12b31","title":"Clinical Effects","mono":"<b>ORAL CONTRACEPTIVES <\/b><br\/>USES: To suppress the follicle-stimulating hormone luteinizing hormone sequence from the anterior pituitary, resulting in the suppression of ovulation and production of mucus that is less acceptable to spermatozoa. PHARMACOLOGY: An oral contraceptive acts by suppression of gonadotropins. TOXICOLOGY: There are no significant toxic effects from overdose. OVERDOSE: Abdominal pain, nausea, vomiting, headaches, breast tenderness, dysmenorrhea, arterial thromboembolism, hypertension, venous thrombosis, pulmonary embolus, cerebral thrombosis. ADVERSE EFFECTS: Nausea and vomiting with iron containing contraceptives in children, otherwise asymptomatic. <br\/>"},{"id":"8smcs12b32","title":"Treatment","mono":"<b>ORAL CONTRACEPTIVES <\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: The vast majority of oral contraceptive overdoses require only supportive care. MANAGEMENT OF SEVERE TOXICITY: Severe toxicity is not expected in single substance oral contraceptive ingestion.<\/li><li>Decontamination: There is no need for GI decontamination.<\/li><li>Airway management: Patients with single substance oral contraceptive ingestion will not require airway management.<\/li><li>Antidote: None.<\/li><li>Enhanced elimination procedure: Hemodialysis and hemoperfusion are not of value.<\/li><li>Monitoring of patient: Concentrations of the hormones in oral contraceptives are not clinically useful. No routine laboratory studies are needed in most patients.<\/li><li>Patient disposition: HOME CRITERIA: Patients with inadvertent ingestions can be managed at home. If oral contraceptives containing iron are ingested, asymptomatic patients ingesting less than 40 mg\/kg elemental iron can be managed at home. OBSERVATION CRITERIA: The following patients should be sent to a healthcare facility for evaluation: Patients with self-harm ingestions; patients ingesting iron-containing oral contraceptives at a dose of more than 40 mg\/kg elemental iron or who have symptoms (nausea, vomiting, or other gastrointestinal complaints). ADMISSION CRITERIA: Patients with pure oral contraceptive overdoses do not need admission. Children with exposure to iron-containing products should follow the iron guidelines for admission. CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance in managing patients for any additional questions.<\/li><\/ul>"},{"id":"8smcs12b33","title":"Range of Toxicity","mono":"<b>ORAL CONTRACEPTIVES <\/b><br\/>TOXICITY: A human toxic dose has not been established. Significant toxicity has not been reported after overdose. THERAPEUTIC DOSE: Oral contraceptives are available in various brands, doses, and formulations. <br\/>"}]},{"id":"8smcs13","title":"Clinical Teaching","mono":"<ul><li>Warn patient to report symptoms of venous or arterial thrombosis.<\/li><li>Instruct patient to report symptoms of gallbladder disease or jaundice.<\/li><li>Counsel patient to report any irregularities in vaginal bleeding.<\/li><li>Side effects may include headache, migraine, abdominal pain, flatulence, vaginal infection, genital discharge, breast discharge, breast pain or enlargement, mood disorders, nervousness, chloasma, and weight changes.<\/li><li>Advise patient to take tablet at the same time every day.<\/li><li>Instruct patient that if a single active dose is missed, including vomiting or diarrhea within 3 to 4 hours after the active dose, take the tablet as soon as possible and resume a normal schedule. If more than one active dose is missed, contact a physician for instructions. Use of additional nonhormonal methods of contraception may be necessary.<\/li><\/ul>"}]}